January 19, 2018 5:20pm

The sector opened neutral <19/19 and 2 flats>, was up at the mid-day <21/17 and 2 flats> and closed positive (21/18 and 1 flat)

While the IBB (+0.73%), XLV (+0.41%), XBI (+1.17%), IWM (+1.32%) with the NADAQ (+0.55%) were UP

 

What’s a good price for individual sector equities?

It’s still based on fundamental and speculative opinions which have major limits of their own.

 

Pre-open indications: 5 hits and 0 miss

 

Out and about: The Biostage (BSTG +$0.10) chronicles … don’t be fooled by surges!

Friday’s results have implications to Monday’s sector activity as a daily report may say little or a lot and it serves as insurance that all indications are being examined and evaluated!

 

Henry’omics:

From the pre-open’s newsletter, “…John Maynard Keynes said “When my information changes,”, “I change my mind. What do you do?” When pricing elevates, I calculate an “Icarus” effect! Reliable information on the issues of the day is a scarce commodity; it’s not about headline writers but, the business of making the unseen visible … To be right so often, can’t be provided every day unless one is grounded in providing the evidence of sector and market realities!”

Reiterating, “Management teams BETTER start rethinking their … APPEAL to shareholders! Algorithms and ETFs don’t talk … but, they do buy and sell every day.”

The Dow and NASDAQ were both up 1% for the week, and the S&P was up 0.9% over the same period.

 

The week’s cell therapy sector’s record over 5 sessions (of 40 covered companies):

·         Friday closed closely positive with 18 decliners, 21 advancers and 1 flat;             

·         Thursday closed NEGATIVE with 20 decliners, 15 advancers and 5 flats;

·         Wednesday closed barely POSITIVE with 18 decliners, 19 advancers and 3 flats;

·         Tuesday closed NEGATIVE with 31 decliners, 9 advancers and 0 flats;

·         Monday was a market holiday

 

While we shuttled back and forth from negative to barely or closely positive closes!

  • The RegMed, stem and cell therapy sector in the New Year 2018 is unfolding finding they never have been less secure as to share pricing!

With investor anger rising, ETFS and algorithms are taking more than their pound of flesh on a daily basis of investor dollars.

  • Which opens the door to a question … who is the human face of the sector and companies themselves – name a list of companies and their CEOs and you will be stumped in four out of five!

The real question is, do investors recognize the risks inherent in “our” universe

While pumped-up claims  and pricing performanc are everyday assaults on investor’s sense of pricing as they CRASH!

 

 

The advance/decline line scenario of 40 SCGT & RT covered companies:   

·         The open was neutral with an A/DL of 19/19 and 2 flat ;

·         The mid-day was positive with an A/DL of 21/17 and 2 flat;

·         The close was positive  with an A/DL of21/18 and 1 flat;

 

Pre-open indications:

  • bluebird bio (BLUE) closed down -$6.15 – hit;
  • Intrexon (XON) closed down -$0.63 – hit;
  • Juno Therapeutics (JUNO) closed down -$3.56 – hit;
  • MiMedx (MDXG) closed down -$0.06 – hit;
  • Sangamo Therapeutics (SGMO) closed up + $0.25 – hit;

 

MY working trend lines:

… The greatest volume to the downside:  CYTX, XON, JUNO, NWBO and MDXG

… Upside volume was weighted to:  RENE.L, IMUC, ONVO, ADVM and SGMO

… Biggest $ downside: BLUE (-$6.15), JUNO (-$3.56), XON (-$0.63), RGNX (-$0.45) and CLLS (-$0.41)

… Largest $ upside:  ONCE (+$0.71), AXGN (+$0.70), ADRO (+$0.40), VCEL (+$0.25) and SGMO (+$0.25)

… Flat: AST

 

Out and about:

Biostage (BSTGD) This management team WIPED OUT 20 M of holder’s shares and investment!

Opened at $2.66 (previous closed $2.60) closed +$0.10 or +3.85% in a day’s range of $2.40 to $2.87 to close at $2.70 with low 18,342 shares traded.  This follows the projected $1.32 post the 1-to-20 reverse split – a $4 M in-flow just followed a $30 M investment loss incurring a $47 M deficit!

NO scientists, a CEO, CFO and 2 accountants don’t make a company who couldn’t pay their rent or communicate their issues to past “fleeced” shareholders …

I am NOT “eating” my negative declaration, my OPINION is still “COVER UP of male and female harassment and corporate MISDEEDS “by members of management team!

What did happen to (reasons) and the story “around” the IND NOT being filed and the cmo and president leaving the company? NEVER forget the storyline of the 2 broken financings before the reverse split!

http://app.quotemedia.com/data/downloadFiling?webmasterId=101533&ref=11980760&type=HTML&symbol=BSTGD&companyName=Biostage&formType=3&dateFiled=2018-01-10&cik=0001563665 – VERY interesting, NO mention of BSTG’s executives!

 

 

Daily analytics:

Stock indexes rose on Friday to finish the week strong, with even fears of a government shutdown failing to dampen bullish investor sentiment.

·         The Dow advanced 54 points, or 0.2%, to 26,072.

·         The NASDAQ added 40 points, or 0.6%, to 7,336.

·         The S&P 500 rose 12 points, or 0.4%, to 2,810.

 

The CBOE Volatility Index (VIX) widely considered the best gauge of fear in the market, Friday traded at 11.20, down -8.35% …

  • Thursday traded at 12.22, up +2.60% after Wednesday traded at 11.91, up +2.14% after Tuesday traded at 11.66, up +14.76% after last Friday traded at 10.15, up +2.73%, …

 

Welcome to another day of the sector’s roller coaster …

… The iShares Russell 2000 (IWM) indicated:

·         Friday was up +1.32%

·         Thursday  -0.70%

·         Wednesday +0.96%

·         Tuesday was -1.25%

·         Monday was a market holiday;

·         Last Friday was up +0.40%

 

… The iShares NASDAQ Biotechnology (IBB) indicated:

·         Friday was up +0.66%

·         Thursday was down -0.13%

·         Wednesday was up +0.73%

·         Tuesday was -1.38%

·         Monday was a holiday;

·         Last Friday was up +0.67%

 

 

The count - decliners versus gainers: 

... look at the differences in decliners:

·         Friday’s decliners ranged from -0.06% <QURE -$0.01> to -7.88% <ISCO -$0.13> in 18 equities;

·         Thursday’s decliners ranged from -0.37% <STML -$0.05> to -9.68% <RENE.L -$0.15> in 20 equities;

·         Wednesday’s decliners ranged from -0.12% <BLCM -$0.01> to -6.75% <ISCO -$0.11> in 18 equities;

·         Tuesday’s decliners ranged from -0.61% <ISCO -$0.01> to -9.03% <RGNX -$2.75> in 31 equities;

·         Monday was a holiday;

·         Last Friday’s decliners ranged from -0.51% <ATHX -$0.01> to -7.28% <CYTX -$0.028> in 21 equities;

Versus

… Look at the percentage’s (%) and spreads …

·         Friday’s gainers ranged from +0.67% <PSTI +$0.01> to +5.80% <ADRO +$0.40> in 21 equities;

·         Thursday’s gainers ranged from +0.17% <MESO +$0.01> to +18.31% <CYTX +$0.06> in 15 equities;

·         Wednesday’s gainers ranged from +0.33% <VSTM +$0.01> to +53.86% <JUNO +$23.65> in 19 equities;

·         Tuesday’s gainers ranged from +0.58% <MDXG +$0.08> to +10.13% <ADVM +$0.40> in 9 equities;

·         Monday was a holiday;

·         Last Friday’s gainers ranged from +0.67% <BLCM +$0.06> to +11.27% <XON +$1.49> in 19 equities;

 

                                  

Opinions expressed are those of the author and are subject to change, and not intended to be a forecast of future events, a guarantee of future results, nor investment advice.

Whether information or intelligence is good, bad or somewhere in between; I put into context what is relevant and useful for investors.  All investments are subject to risks. Investors should consider investment objectives.

Henry McCusker, the editor and publisher of RegMed Investors does not hold or have positions in securities referred to in this publication.